Composition, form of production and packaging
Tablets are round, biconcave, white or almost white, odorless.
1 tab. (1 dose)
bacterial ribosomes titrated up to 70% ribonucleic acid 750 Ојg,
in t.ch. ribosomes Klebsiella pneumoniae 3.5 shares
Ribosomes Streptococcus pneumoniae 3.0 shares
ribosomes Streptococcus pyogenes 3.0 share
ribosomes Haemophilus influenzae 0.5 fraction
proteoglycans of the membrane part of Klebsiella pneumoniae 1.125 mg (15 lobes)
[PRING] silicon colloidal hydrophobic, magnesium stearate, sorbitol.
4 things. - blisters (1) - packs of cardboard.
Granules for solution for ingestion of white color, odorless.
1 pack.
bacterial ribosomes titrated up to 70% ribonucleic acid 750 Ојg,
in t.ch. ribosomes Klebsiella pneumoniae 3.5 shares
Ribosomes Streptococcus pneumoniae 3.0 shares
ribosomes Streptococcus pyogenes 3.0 share
ribosomes Haemophilus influenzae 0.5 fraction
proteoglycans of the membrane part of Klebsiella pneumoniae 1.125 mg (15 lobes)
[PRING] polyvidone, mannitol (D-mannitol).
Sachets from the combined material (4) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
Immunomodulator of bacterial origin. Ribomunil is a ribosomal-proteoglycan complex, which includes the most common pathogens of infections of the ENT organs and respiratory tract, and refers to stimulators of specific and nonspecific immunity.
The ribosomes included in the preparation contain antigens identical to the surface antigens of bacteria, and when ingested they cause the formation of specific antibodies to these pathogens (the effect of the vaccine). Membrane proteoglycans stimulate nonspecific immunity, which is manifested in the amplification of phagocytic activity of macrophages and polynucleated leukocytes, increasing factors of nonspecific resistance. The drug stimulates the function of T- and B-lymphocytes, the production of serum and secretory immunoglobulins such as IgA, interleukin-1, as well as alpha and gamma interferons. This explains the preventive effect of Ribomunyl for respiratory viral infections.
The use of Ribomunil in complex therapy allows to increase the efficiency and reduce the duration of treatment, significantly reduce the need for antibiotics, bronchodilators, and increase the period of remission.
PHARMACOKINETICS
Data on the pharmacokinetics of Ribomunil are not available.
INDICATIONS
- prevention and treatment of recurrent infections of the ENT organs (otitis, rhinitis, sinusitis, pharyngitis, laryngitis, angina) and respiratory tract (chronic bronchitis, tracheitis, pneumonia, infectious-dependent bronchial asthma) in patients older than 6 months;
- prevention of recurrent infections in patients at risk (often and long-term sick, before the beginning of the autumn-winter season, especially in ecologically unfavorable regions, patients with chronic diseases of ENT organs, chronic bronchitis, bronchial asthma, including children older than 6 months and the elderly).
DOSING MODE
Adults and children over 6 months of the drug prescribed 1 time / day in the morning on an empty stomach.
Single dose (regardless of age) is 1 tab. by 0.75 mg (with a single dose), or granules from 1 sachet, previously dissolved by boiled water at room temperature.
In the first month of treatment and / or for prophylaxis, Ribomunyl is taken on the first 4 days of each week for 3 weeks every day. In the next 2-5 months - the first 4 days of each month.
To children of early age the drug is recommended to be given in the form of granules.
It is recommended to conduct three-month preventive courses of treatment 2 times a year, six-month preventive courses - once a year.
SIDE EFFECT
It is observed rarely, does not require drug withdrawal, is characterized by:
- transient hypersalivation at the beginning of treatment, nausea, vomiting, diarrhea.
- Allergic reactions (hives, angioedema).
CONTRAINDICATIONS
- autoimmune diseases;
- Hypersensitivity to the drug.
PREGNANCY AND LACTATION
Special studies of the safety and efficacy of Ribomunil during pregnancy and lactation were not conducted.
The use of Ribomunil in pregnancy and lactation (breastfeeding) is possible only after evaluating the intended benefit to the mother and the potential risk to the fetus and the baby.
APPLICATION FOR CHILDREN
It is used in children older than 6 months.
SPECIAL INSTRUCTIONS
Patients should be warned about the possibility of transient elevation of body temperature on day 2-3, which is a manifestation of the therapeutic effect of the drug and does not usually require cessation of treatment. Increased temperature can sometimes be accompanied by minor and transient symptoms of ENT organ infections.
OVERDOSE
At present, no cases of an overdose of Ribomunil have been reported.
DRUG INTERACTION
Until now, the clinically significant drug interaction of the drug Ribomunil has not been described.
Ribomunil can be combined with other medicines (antibiotics, bronchodilators, anti-inflammatory drugs).
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a place inaccessible to children and transported (by all types of indoor transport) at a temperature of 15 В° to 25 В° C. Shelf life - 3 years.
